GW501516 Reduces Inflammation in Kidney Disease Mice
Author Information
Author(s): Yang Xu, Kume Shinji, Tanaka Yuki, Isshiki Keiji, Araki Shin-ichi, Chin-Kanasaki Masami, Sugimoto Toshiro, Koya Daisuke, Haneda Masakazu, Sugaya Takeshi, Li Detian, Han Ping, Nishio Yoshihiko, Kashiwagi Atsunori, Maegawa Hiroshi, Uzu Takashi
Primary Institution: Shiga University of Medical Science
Hypothesis
Can GW501516, a PPARδ agonist, reduce tubulointerstitial inflammation in proteinuric kidney disease?
Conclusion
GW501516 has an anti-inflammatory effect in renal tubular cells and may help treat proteinuric kidney diseases.
Supporting Evidence
- GW501516 treatment reduced tubular damage in mice with protein overload.
- Inflammatory cytokines like MCP-1 and TNFα were significantly lower in GW501516-treated mice.
- GW501516 inhibited the TAK1-NFκB signaling pathway in renal cells.
Takeaway
This study shows that a drug called GW501516 can help reduce inflammation in the kidneys of mice with a specific type of kidney disease.
Methodology
Mice were treated with GW501516 and subjected to protein overload to assess kidney inflammation and damage.
Limitations
The study was conducted in mice, and results may not directly translate to humans.
Participant Demographics
Male C57BL/6 mice were used in the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website